A computer-implemented method of visualizing blood flow through a patient using magnetic resonance imaging (MRI) includes receiving an image of the portal venous system of the patient's liver at a full field of view. A reduced field of view is defined which encompasses the portal venous system of the patient's liver and excludes extraneous anatomy in the full field of view. A navigator area is defined in the full field of view and outside of the reduced field of view. Transmit channels are used to selectively excite the reduced field of view and the navigator area throughout a cardiac cycle of the patient. Measurement data is acquired in response to the selective excitation. The acquired data is used to generate time-resolved 3D datasets. Additionally, a 3D visualization of blood flow though the portal venous system is generated based on the time-resolved 3D datasets.

The present invention provides, among other things, methods of identifying cancerous or pre-cancerous tissue including providing a first region of tissue from a subject, calculating a roughness exponent for the first region of tissue, and comparing the roughness exponent of the first region of tissue to 0.5, wherein a difference of less than 0.2 between the roughness exponent of the first region of tissue and 0.5 indicates that the tissue is cancerous or pre-cancerous. Additionally, the present invention provides methods including providing a first view of a region of tissue, providing a second view of a region of tissue, calculating a first fractal dimension for the first view of the region of tissue, and calculating a second fractal dimension for the second view of the region of tissue, wherein if the fractal dimension of at least one of the first fractal dimension and the second fractal dimension is in the fractal zone, the region of tissue is considered cancerous. Also provided are systems for performing these assessments.

A composition comprising: a polymorphic form of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-ulfonatobutyl)-3H-indol- 1- ium-5-sulfonate or 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate and an acceptable excipient.

Described herein are systems and methods for performing multi-parametric diagnosis for liver disease. Systems and methods as described herein can include positioning a subject-in association with a medical imaging device and using the medical imaging device to measure the subject's liver for extracellular fluid and iron content. Systems and methods as described herein can further include determining whether iron overload may be indicated or present from the measurement for iron content, and if indicated, correcting the measurement for extra cellular fluid. Systems and methods as described herein can further include measuring the liver for hepatic lipid content (HLC). Systems and methods as described herein can determine the presence or absence of liver disease from measurements obtained from a subject. In certain embodiments, the medical imaging device is a magnetic resonance (MR) scanner. In certain embodiments, the liver is measured for iron overload.

A method of predicting bile flow through a liver is described. The method comprises: (a) dividing the axis connecting the central vein and a portal vein of a lobule into zones; (b) measuring secretion of bile by hepatocytes; (c) calculating the transport rate of said bile of (b) through each of the zones defined in (a), using differential equations; (d) providing a three-dimensional representation of the bile canaliculi in said lobule; (e) calculating a correction factor as the ratio between hydraulic radius and geometric radius of said bile canaliculi; and (f) calculating bile transport through (f-i) said three-dimensional representation of (d) using the transport rates determined in step (c) and said correction factor calculated in step (e), by solving the Navier-Stokes equations for said representation of (d); or (f-ii) a porous medium model of said liver lobule using the transport rates determined in step (c).

A method for organ imaging, comprising: administering to a subject a diagnostic effective amount of 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-phenoxycyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate or 2-((E)-2-((E)-3-(2-((E)-3,3-dimethyl-5-sulfonato-1-(4-sulfonatobutyl)indolin-2-ylidene)ethylidene)-2-(4-sulfonatophenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfonatobutyl)-3H-indol-1-ium-5-sulfonate. In one embodiment, the organ includes one or more of kidney, bladder, liver, gall bladder, spleen, intestine, heart, lungs and muscle.

A method and system (100) for augmented interpretation of shear wave elastography between first and second imaging modalities comprises performing an elastography measurement via a second imaging modality (20), different from a first imaging modality (10), to obtain at least one second imaging modality elastography value (32, 60) of a region of interest (33). At least one corresponding first imaging modality elastography value (36, 38, 62) is predicted based on the obtained second imaging modality elastography value. A graphical user interface or smart report dashboard (50) is generated that shows (i) a fibrosis level (521) of the region of interest, wherein the fibrosis level is determined as a function of (i)(a) the at least one second imaging modality elastography value (32) and/or (i)(b) the predicted at least one corresponding first imaging modality elastography value (36, 38).

A system, method, and computer program product for predicting, anticipating, and/or assessing tissue characteristics obtains measurement information associated with a parameter of a voxel of tissue of a patient measured at two or more time points, the two or more time points occurring before one or more characteristics of the voxel of the tissue are separable in an image generated based on the parameter of the voxel measured at a single time point of the two or more time points, and determines, based on the parameter of the voxel at the two or more time points, the one or more characteristics of the voxel of the tissue.

An analysis apparatus includes processing circuitry configured to obtain quantitative values of a plurality of types of tissue properties relating to a region of interest of a subject, and generate a diagram of the region of interest based on the quantitative values.

Embodiments relate to surgical systems and methods. The system includes a main assembly having an IMU subsystem, camera, scope head assembly, and processor. Processor processes images and IMU information, including determining whether images include a distal end of the scope head assembly and a cannulation target. Responsive to a determination that images include the distal end of the scope head assembly, the processor generates 3-dimensional position of distal end of the scope head assembly. When images are determined to include the cannulation target, the processor generates 3-dimensional positions of the cannulation target. Processor also generates predictions of one or more real-time trajectory paths for the distal end of the scope head assembly to cannulate the cannulation target.